Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment

Robert H. Berndsen, U. Kulsoom Abdul, Andrea Weiss, Marloes Zoetemelk, Marije T. te Winkel, Paul J. Dyson, Arjan W. Griffioen, Patrycja Nowak-Sliwinska

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Cancer cells are often dependent on epigenetic pathways for their survival. Consequently, drugs that target the epigenome, rather than the underlying DNA sequence, are currently attracting considerable attention. In recent years, the first epigenetic drugs have been approved for cancer chemotherapy, mainly for hematological applications. Limitations in single-drug efficacies have thus far limited their application in the treatment of solid tumors. Nevertheless, promising activity for these compounds has been suggested when combined with other, distinctly targeted agents. In this review, we discuss the anti-angiogenic activity of histone deacetylase and DNA methyltransferase inhibitors and their combinations with other targeted (anti-angiogenic) therapeutics in treatment of solid tumors. The role that these inhibitors play in the inhibition of tumor angiogenesis, particularly in combination with other targeted agents, and the advantages they present over broad acting anticancer agents, are critically discussed.

Original languageEnglish
Pages (from-to)245-267
Number of pages23
JournalAngiogenesis
Volume20
Issue number2
DOIs
Publication statusPublished - 1 May 2017

Cite this

Berndsen, R. H., Abdul, U. K., Weiss, A., Zoetemelk, M., te Winkel, M. T., Dyson, P. J., ... Nowak-Sliwinska, P. (2017). Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment. Angiogenesis, 20(2), 245-267. https://doi.org/10.1007/s10456-017-9551-z
Berndsen, Robert H. ; Abdul, U. Kulsoom ; Weiss, Andrea ; Zoetemelk, Marloes ; te Winkel, Marije T. ; Dyson, Paul J. ; Griffioen, Arjan W. ; Nowak-Sliwinska, Patrycja. / Epigenetic approach for angiostatic therapy : promising combinations for cancer treatment. In: Angiogenesis. 2017 ; Vol. 20, No. 2. pp. 245-267.
@article{d6cc9f10f3084603bd69fe20c2cf3c1b,
title = "Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment",
abstract = "Cancer cells are often dependent on epigenetic pathways for their survival. Consequently, drugs that target the epigenome, rather than the underlying DNA sequence, are currently attracting considerable attention. In recent years, the first epigenetic drugs have been approved for cancer chemotherapy, mainly for hematological applications. Limitations in single-drug efficacies have thus far limited their application in the treatment of solid tumors. Nevertheless, promising activity for these compounds has been suggested when combined with other, distinctly targeted agents. In this review, we discuss the anti-angiogenic activity of histone deacetylase and DNA methyltransferase inhibitors and their combinations with other targeted (anti-angiogenic) therapeutics in treatment of solid tumors. The role that these inhibitors play in the inhibition of tumor angiogenesis, particularly in combination with other targeted agents, and the advantages they present over broad acting anticancer agents, are critically discussed.",
keywords = "Anti-angiogenesis, Clinical trials, Combination therapy, DNA methyltransferase inhibitors, Epi-drugs, Histone deacetylase inhibitors, Solid tumors, Tumor vasculature",
author = "Berndsen, {Robert H.} and Abdul, {U. Kulsoom} and Andrea Weiss and Marloes Zoetemelk and {te Winkel}, {Marije T.} and Dyson, {Paul J.} and Griffioen, {Arjan W.} and Patrycja Nowak-Sliwinska",
year = "2017",
month = "5",
day = "1",
doi = "10.1007/s10456-017-9551-z",
language = "English",
volume = "20",
pages = "245--267",
journal = "Angiogenesis",
issn = "0969-6970",
publisher = "Springer Netherlands",
number = "2",

}

Berndsen, RH, Abdul, UK, Weiss, A, Zoetemelk, M, te Winkel, MT, Dyson, PJ, Griffioen, AW & Nowak-Sliwinska, P 2017, 'Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment' Angiogenesis, vol. 20, no. 2, pp. 245-267. https://doi.org/10.1007/s10456-017-9551-z

Epigenetic approach for angiostatic therapy : promising combinations for cancer treatment. / Berndsen, Robert H.; Abdul, U. Kulsoom; Weiss, Andrea; Zoetemelk, Marloes; te Winkel, Marije T.; Dyson, Paul J.; Griffioen, Arjan W.; Nowak-Sliwinska, Patrycja.

In: Angiogenesis, Vol. 20, No. 2, 01.05.2017, p. 245-267.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Epigenetic approach for angiostatic therapy

T2 - promising combinations for cancer treatment

AU - Berndsen, Robert H.

AU - Abdul, U. Kulsoom

AU - Weiss, Andrea

AU - Zoetemelk, Marloes

AU - te Winkel, Marije T.

AU - Dyson, Paul J.

AU - Griffioen, Arjan W.

AU - Nowak-Sliwinska, Patrycja

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Cancer cells are often dependent on epigenetic pathways for their survival. Consequently, drugs that target the epigenome, rather than the underlying DNA sequence, are currently attracting considerable attention. In recent years, the first epigenetic drugs have been approved for cancer chemotherapy, mainly for hematological applications. Limitations in single-drug efficacies have thus far limited their application in the treatment of solid tumors. Nevertheless, promising activity for these compounds has been suggested when combined with other, distinctly targeted agents. In this review, we discuss the anti-angiogenic activity of histone deacetylase and DNA methyltransferase inhibitors and their combinations with other targeted (anti-angiogenic) therapeutics in treatment of solid tumors. The role that these inhibitors play in the inhibition of tumor angiogenesis, particularly in combination with other targeted agents, and the advantages they present over broad acting anticancer agents, are critically discussed.

AB - Cancer cells are often dependent on epigenetic pathways for their survival. Consequently, drugs that target the epigenome, rather than the underlying DNA sequence, are currently attracting considerable attention. In recent years, the first epigenetic drugs have been approved for cancer chemotherapy, mainly for hematological applications. Limitations in single-drug efficacies have thus far limited their application in the treatment of solid tumors. Nevertheless, promising activity for these compounds has been suggested when combined with other, distinctly targeted agents. In this review, we discuss the anti-angiogenic activity of histone deacetylase and DNA methyltransferase inhibitors and their combinations with other targeted (anti-angiogenic) therapeutics in treatment of solid tumors. The role that these inhibitors play in the inhibition of tumor angiogenesis, particularly in combination with other targeted agents, and the advantages they present over broad acting anticancer agents, are critically discussed.

KW - Anti-angiogenesis

KW - Clinical trials

KW - Combination therapy

KW - DNA methyltransferase inhibitors

KW - Epi-drugs

KW - Histone deacetylase inhibitors

KW - Solid tumors

KW - Tumor vasculature

UR - http://www.scopus.com/inward/record.url?scp=85017101403&partnerID=8YFLogxK

U2 - 10.1007/s10456-017-9551-z

DO - 10.1007/s10456-017-9551-z

M3 - Review article

VL - 20

SP - 245

EP - 267

JO - Angiogenesis

JF - Angiogenesis

SN - 0969-6970

IS - 2

ER -

Berndsen RH, Abdul UK, Weiss A, Zoetemelk M, te Winkel MT, Dyson PJ et al. Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment. Angiogenesis. 2017 May 1;20(2):245-267. https://doi.org/10.1007/s10456-017-9551-z